SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection

Cohen, Carolyn A.; Li, Athena P. Y.; Hachim, Asmaa; Hui, David S. C.; Kwan, Mike Y. W.; Tsang, Owen T. Y.; Chiu, Susan S.; Chan, Wai Hung; Yau, Yat Sun; Kavian, Niloufar; Ma, Fionn N. L.; Lau, Eric H. Y.; Cheng, Samuel M. S.; Poon, Leo L. M.; Peiris, Malik; Valkenburg, Sophie A.

doi:10.1038/s41467-021-24938-4

Download PDF

Article
Open access
Published: 29 July 2021

SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection

Nature Communications volume 12, Article number: 4678 (2021) Cite this article

21k Accesses
82 Citations
383 Altmetric
Metrics details

Subjects

Abstract

SARS-CoV-2 infection of children leads to a mild illness and the immunological differences with adults are unclear. Here, we report SARS-CoV-2 specific T cell responses in infected adults and children and find that the acute and memory CD4⁺ T cell responses to structural SARS-CoV-2 proteins increase with age, whereas CD8⁺ T cell responses increase with time post-infection. Infected children have lower CD4⁺ and CD8⁺ T cell responses to SARS-CoV-2 structural and ORF1ab proteins when compared with infected adults, comparable T cell polyfunctionality and reduced CD4⁺ T cell effector memory. Compared with adults, children have lower levels of antibodies to β-coronaviruses, indicating differing baseline immunity. Total T follicular helper responses are increased, whilst monocyte numbers are reduced, indicating rapid adaptive co-ordination of the T and B cell responses and differing levels of inflammation. Therefore, reduced prior β-coronavirus immunity and reduced T cell activation in children might drive milder COVID-19 pathogenesis.

HLA alleles, disease severity, and age associate with T-cell responses following infection with SARS-CoV-2

Article Open access 06 September 2022

Thorunn A. Olafsdottir, Kristbjorg Bjarnadottir, … Kari Stefansson

Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses

Article Open access 25 November 2021

Tiago Fazolo, Karina Lima, … Cristina Bonorino

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Article 15 July 2020

Nina Le Bert, Anthony T. Tan, … Antonio Bertoletti

Introduction

A lack of pre-existing SARS-CoV-2-specific protective antibodies has led to the rapid global spread of the novel coronavirus, however the large majority of infections are reportedly asymptomatic or mild¹. Previous COVID-19 infection may protect from reinfection^2,3 and neutralising antibodies are likely to play an important protective role⁴. However, the emergence of variant strains (e.g., 501Y.V2) suggests the possibility of escape from previous neutralising antibodies^5,6. Antibody-based treatment of established infection has had a minimal beneficial effect on clinical outcome in COVID-19 patients⁷ and may lead to the emergence of escape mutant variants⁸. Dysregulated innate immune responses, such as auto-interferon antibodies or delayed responsiveness have been reported in some severe COVID-19 cases but cannot account for the majority of severe infections^9,10,11. Importantly, a coordinated cellular immune response has been key to the clinical resolution of SARS-CoV-2 infection¹².

Pre-existing cross-reactive antibodies elicited by exposure to endemic human common cold coronaviruses such as the related β-coronavirus OC43 and HKU-1, do not prevent infection with SARS-CoV-2^13,14. Furthermore, pre-existing cross-reactive T cell immunity generated by common cold coronaviruses has also been detected in the majority of people¹⁵, with epitope conservation mostly reported in the ORF1ab nonstructural proteins¹⁶, but SARS-CoV-2 cross-reactive T cell responses have also been detected despite lower (< 67%) epitope homology¹⁷. Upon infection, T cell responses shift towards Spike and Nucleocapsid structural proteins^17,18. However, cross-reactive CD4⁺ T cell responses have been reported as similar¹⁷ or lower avidity and may be associated with worsening clinical outcomes¹⁹. In animal models of reinfection, Spike-specific CD8⁺ T cell responses can compensate for inadequate antibody responses and may provide an immune correlate of protection²⁰. The magnitude of ORF1ab specific SARS-CoV-2 T cell responses during infection of adults does not differ with symptom severity but does associate with reduced duration of illness¹⁸. Therefore, determining the balance and specificity of SARS-CoV-2-specific T cell responses for structural, accessory, and nonstructural proteins may inform the COVID-19 response and pathogenesis.

Following mild COVID-19 infection SARS-CoV-2 specific memory B cells are established for at least 6 months with long-term stability that may be recruited upon reinfection²¹. T cells following SARS-CoV infection in 2003 have reassuringly been detected 17 years after infection¹⁸. Robust adaptive antibody and T cell responses have been reported in symptomatic and asymptomatic SARS-CoV-2 infected adults^22,23. Although serum antibody response to the common cold coronaviruses may be long-lasting, reinfection is common one or more years after infection¹⁴. The severity of COVID-19 may be reduced by rapid and early recruitment of established immune responses^24,25,26. The early and rapid recruitment of T follicular helper (Tfh) cells²⁷ drives early antibody development²⁴ by germinal B cell responses leading to increasing neutralising antibody titers, however increased disease severity is associated with higher viral loads and antibody titers¹⁸. The magnitude of the acute T cell responses in Middle Eastern Respiratory Syndrome (MERS), a related β-coronavirus, is negatively associated with the magnitude of the CD4⁺ T cell response and the duration of illness and thus antigen loads^28,29.

In a small family case study, children (n = 3) exposed to their SARS-CoV-2 infected parents displayed coordinated recruitment of total T cells and specific antibodies however infection was not able to be virologically confirmed²⁶. Asymptomatic infection may represent a large proportion of SARS-CoV-2 infections, particularly in children. The immunological differences of cellular recruitment for children and adults have not been sufficiently characterised to determine the immunological basis of differing diseases severity and outcomes of COVID-19.

In Hong Kong, effective public health measures of a track, trace, quarantine of returned travellers, and testing of quarantined close contacts have led to the identification of RT-PCR confirmed asymptomatic infections, even in young children. In this study, we assessed the balance of specificity, memory phenotype, cytokine quality, and longitudinal stability of SARS-CoV-2 T cell responses in children (aged 2–13 years old) and adults with asymptomatic or symptomatic infection to address the role of T cells in the pathogenesis of milder disease in children.

Results

SARS-CoV-2-induced CD4⁺ T cell responses to structural proteins

SARS-CoV-2 specific T cell responses were assessed from COVID-19 cases in children and adults, and in adult negative controls. SARS-CoV-2 consists of 4 structural proteins, an extensive ORF1ab which encodes 16 nonstructural proteins, and 7 accessory proteins. The relative expression of the structural proteins versus accessory and nonstructural proteins during SARS-CoV-2 virus replication may impact their immunogenicity. Cross-reactivity with common cold viruses¹⁴ may also affect the magnitude of T cell responses elicited. Due to the limited cell numbers of our samples, peptide or protein-specific mapping was not possible. Therefore direct ex vivo CD4⁺ and CD8⁺ T cell responses were assessed for overlapping peptide pools of structural, accessory, and ORF1ab proteins respectively, (Fig. 1b) using IFNγ production, a key anti-viral cytokine as a read-out for specificity (Fig. 1c). Paired samples from SARS-CoV-2 infected adults at hospital admission (time 1) and discharge (time 2) showed an increase in structural specific IFNγ⁺ CD4⁺ T cells (Fig. 1d, p = 0.0012, Wilcoxon two-tailed matched-pairs test, Fig. 1f, fold change p = 0.0005, two-tailed one-sample Wilcoxon test) and to a lesser extent CD8⁺ T cells (Fig. 1e, p = 0.2579, Wilcoxon two-tailed matched-pairs test; Fig. 1f, fold change p = 0.0230, two-tailed one-sample Wilcoxon test).

**Fig. 1: Infected children have lower CD4⁺ and CD8⁺ T cell responses than adults.**

To confirm the appropriate use of IFNγ production as a surrogate measure of virus-specific T cell responses, three assays were initially used. T cell responses from infected children and adults (memory time point samples, > day 14) and negative controls of both children and adults for CD4⁺ T cells were measured for IFNγ production, IL-4 production, and expression of activation-induced markers (AIM by CD40L⁺ CD69⁺ CD137⁺ OX40⁺, negative adults only) and CD8⁺ T cells responses were measured by IFNγ production and AIM expression (Fig. 1g). IFNγ and AIM assays also showed higher responses in infected adults compared with negative adults confirming assay specificity. All assays showed that infected adults had greater structural specific T cell responses than infected children (Mann–Whitney two-tailed test). However, the low magnitude of T cell responses directly ex vivo from infected children showed no significant difference to uninfected children. IFNγ CD8⁺ T cells responses further showed a difference between negative children and negative adults, but there was no difference between infected and control groups of either age group. Uninfected children had significantly lower IFNγ⁺ CD8⁺ T cell responses than uninfected adults (Fig. 1g), which is in agreement with our hypothesis that children have lower cross-reactive CD8⁺ T cell memory with lower prior common cold coronavirus exposure. IFNγ and IL4 T cell responses are distinct cell populations with no correlation between responses (Fig. 1h).

The magnitude of SARS-CoV-2 specific CD4⁺ (Fig. 2a) and CD8⁺ (Fig. 2b) T cells for structural, accessory, and ORF1ab proteins was compared between adult patients versus adult negative controls to establish assay specificity and cross-reactivity. We then compared the T cell responses of the adult infections versus paediatric infections to define differences with age. The IFNγ ⁺ CD4⁺ T cell responses towards structural proteins of SARS-CoV-2 were significantly increased in adults (mean±stdev: 0.0533 ± 0.0549%), compared to both children (0.0240 ± 0.0292%, p = 0.0065, Mann–Whitney two-tailed test) and adult negative controls (0.0013 ± 0.0005%, p < 0.0001, Mann–Whitney two-tailed test) (Fig. 2a). The majority of infected adults (94.3%) mounted structural-specific CD4⁺ T cell responses (above DMSO background) (Fig. 2c), whilst only 79.4% of infected children and 50% of adult negative controls had such responses (Fig. 2c). Despite the higher magnitude of responses to structural proteins in infected adults than children, the proportion of responders against each peptide pool was not significantly different between adults and children, except for structural CD8⁺ T cell responses (Fig. 2c). Therefore, the majority of our later analyses focusses on structural specific T cell responses.

**Fig. 2: Specificity of T cell responses in adults and children.**

The accessory-specific CD4⁺ T cell response was comparable in infected children, infected adults, and adult negative controls (Fig. 2a). In infected adults, the structural-protein-specific CD4⁺ T cell responses (86.6%) contributed most to the SARS-CoV-2 specific response (Fig. 2d), than ORF1ab (9.6%) and accessory (3.8%) responses. By contrast, the SARS-CoV-2 specific response in infected children’s CD4⁺ T cell responses was dominated more by ORF1ab (51.8%) than structural specific responses (43.7%). Responses from adult negative controls that recognised SARS-CoV-2 peptides were predominately specific for accessory peptides (90.1%), however the total response was very low in magnitude, at only 0.013±0.02% of CD4⁺ T cells (Fig. 2d).

Infected adults did not have significantly higher CD8⁺ T cell responses compared to adult negative controls (Fig. 2b) indicating cross-reactivity and little amplification of SARS-CoV-2 CD8⁺ T cell responses by infection (Figure 1e, f). But infected children had significantly reduced CD8⁺ T cell responses compared to infected adults for structural and ORF1ab responses (Fig. 2b).

Furthermore, the stratification of subjects for asymptomatic and symptomatic infection did not reveal any further significant differences for T cell response magnitude (Supplementary Figure 2a, b) or contribution of peptide specificities (Supplementary Figure 2c, d) between controls and COVID-19 adults and children.

However, baseline differences exist between adults and children for nonspecific T cell activation^30,31,32. The baseline activation (by DMSO) (Fig. 3a) and overall maximum activation (by PMA/ionomycin) (Fig. 3b) are lower in infected children. Overall background and maximum T cell responsiveness significantly increase with age in infected subjects (Fig. 3c, d). Adult negative controls had comparable background IFNγ induction compared to infected adults (Fig. 3a), but significantly higher maximum responsiveness (Fig. 3b). Whereas negative children had significantly higher nonspecific (for CD4⁺ T cells) and maximum activation than infected children, yet structural specific IFNγ⁺ T cell activation was not different between these groups (Fig. 1g). Therefore, normalisation of structural specific T cells by % of maximum PMA/ionomycin responses after background DMSO subtraction shows that infected adults continue to have higher virus-specific CD4⁺ and CD8⁺ IFNγ T cell responses than children, whilst negative adults also have a higher response than negative children. This normalised response shows a significant difference between infected and uninfected children, and infected and uninfected adults for the CD4⁺ but not CD8⁺ IFNγ T cell response (Fig. 3e). Overall, even with normalisation infected children still have lower CD4⁺ and CD8⁺ T cell responses than infected adults. The fine specificity of identifying low-frequency antigen-specific T cells directly ex vivo may be obscured through normalisation, and maximal activation is refractory to recent infection, therefore T cell responses should be considered directly ex vivo with paired DMSO background subtracted.

**Fig. 3: Non-specific T cell responses increase with age in infected donors.**

Recruitment of early cellular responses

Coordination of the early acute response to SARS-CoV-2 infection is important to drive innate responses³³, and early antibody production²⁴ for improved patient outcomes. Therefore, we assessed the recruitment and activation of monocytes, total Tfh cells, and plasmablasts (also known as antibody-producing cells) during acute (< 14 days post-infection) and convalescent (15–57 days post-infection) SARS-CoV-2 infection in two separate experiments (Fig. 4). At acute time points, the total monocytes showed reduced responses in children compared to infected adults (Fig. 4b), furthermore children had reduced inflammatory type monocytes (Fig. 4c), where these have been found to also be elevated in COVID-19 patients, but lower in severe outcomes in adults^33,34. Meanwhile, infected children and adults showed comparable levels of monocyte recruitment from bone marrow (CCR2) compared to infected adults (Fig. 4d). Overall, negative children and negative adults had equivalent monocyte populations (Fig. 4f–h).

**Fig. 4: Cellular recruitment of Tfh cell, plasmablasts, and monocytes.**

The coordinated recruitment of circulating Tfh for germinal centre reactions and early antibody production by plasmablasts is associated with seroconversion³⁵. The early activated (ICOS⁺ PD-1⁺) total Tfh response was significantly increased in infected children compared to adults and negative controls (Fig. 4e) and remained higher at convalescent time points (Fig. 4k), indicating sustained germinal centre reactions. Whilst plasmablast responses were increased in both children and adults compared to negative controls showing early B cell recruitment with infection (Fig. 4d). At convalescent time points, plasmablast responses in infected children were equivalent to uninfected children, but uninfected children also have significantly higher plasmablast responses than negative adults (Fig. 4j).

T cell responses increase with time post-infection and age

Longitudinal sample collection up to 180 days post-infection enabled us to determine the trend of T cell responses with time post-infection. Long-term stability of durable T cell immunity is likely important to minimise the symptom severity of reinfection with SARS-CoV-2. The CD4⁺ T cell response to structural peptides had stable responses post-infection (Fig. 5a) (r = 0.1475, p = 0.2265, Spearman two-tailed correlation), whilst structural-specific CD8⁺ T cell responses had a moderate significant trend for increased responses with time (Fig. 5B) (r = 0.4194, p = 0.0003, Spearman two-tailed correlation). This was also reflected in the acute fold changes of CD4⁺ and CD8⁺ T cell responses (Fig. 1f), which indicates the CD4⁺ T cell response is recruited early during SARS-CoV-2 infection (Fig. 1d), the CD8⁺ T cell response takes more time to build up with time post-infection. Furthermore, there was no difference in T cell exhaustion (by PD-1 expression) between infected adults and children at either acute or memory responses (Fig. 4).

**Fig. 5: SARS-CoV-2 specific T cell responses increase over time and age.**

The fold change of response magnitude for paired acute responses (< 14 days) to memory time-points (> 14 days) (Fig. 5c, d), showed comparable fold changes in children and adults for CD4⁺ or CD8⁺ T cell response to most viral proteins. Only accessory-specific CD8⁺ T cell responses had a significant decrease in infected children (Fig. 5d). Whilst the acute structural specific CD4⁺ T cell response was significantly increased in adults compared to negative controls (Fig. 5e), the memory CD4⁺ and CD8⁺ T cell response was significantly lower in children compared to infected adults (Fig. 5e, h), resulting in a trend for significantly increased T cell responses with age (Figure 5f, I, j), excluding acute CD8⁺ T cell responses (Figure 5g).

The difference in magnitude of T cell responses with age and time indicates functional differences in T cell recruitment and differentiation, therefore we assessed cytokine polyfunctionality and memory phenotypes. Cytokine polyfunctionality is associated with increased protection from infection for multiple viruses^36,37, and associated with cellular division and terminal differentiation³⁸. Whilst differentiation of T cell memory phenotypes occurs early during infection and can reflect the extent of inflammation³⁹, impacting recall capacity long-term⁴⁰ to infected tissues⁴¹.

Cytokine polyfunctionality of structure-specific T cells (Figure 6a, b) was comparable between adults and children at acute (< 14 days), convalescent (15–60 days), or memory (61–180 days) time points (Fig. 6c), therefore on per-cell basis adults and children had comparable cytokine responses. The phenotype of structure-specific T cells at memory time points (Fig. 6d), however showed that children had reduced T effector memory (TEM) CD4⁺ T cells compared to infected adults (Fig. 6e). The phenotype of structure-specific CD8⁺ T cells was comparable (Fig. 6f).

**Fig. 6: Cytokine polyfunctional quality and memory phenotype.**

Prior common cold coronavirus immunity and cellular responses

The level of coronavirus Spike-specific IgG was determined at early time points (< 14 days) of SARS-CoV-2 infection, to determine if pre-existing immunity impacted T cell responses. The magnitude of α-coronavirus 229E and NL63-specific IgG was comparable between infected children and adults and adult negative controls (Fig. 7a), whilst β-coronavirus HKU-1 and OC43-specific IgG was significantly lower in infected children than infected adults (Fig. 7b). Furthermore, there was no difference in OC43-IgG responses between symptomatic or asymptomatic infections, with significance only being seen between symptomatic adults and children (Fig. 7c). There was a significant correlation of OC43-IgG responses with age (Fig. 7d) (r = 0.6466, p = 0.0002). However, there was no direct significant correlation between OC43-IgG responses and structure-specific CD4⁺ (p = 0.1027, Fig. 7e) or CD8⁺ T cells (p = 0.9729, Fig. 7f). However, there was a borderline moderate negative correlation between OC43-IgG and early acute activated Tfh responses (Fig. 7h) (r = −0.3326, p = 0.0779)¹⁵.

**Fig. 7: Previous exposure to common cold β-coronaviruses and T cell responses.**

Discussion

SARS-CoV-2 infection of children is associated with milder clinical outcomes than adults, and the immune mechanisms are unknown. Several hypotheses have been proposed to explain these differences such as innate cell recruitment and impairment by autoantibodies¹¹, mobilisation of antibody responses, differing levels of pre-existing cross-reactive immunity by common cold coronavirus exposure¹³, or baseline total IgM levels⁴². However, the SARS-CoV-2 T cell compartment in children has so far been under studied²⁶. Viral loads⁴³ and neutralising antibody titers^44,45 are reportedly comparable when age is accounted for, however data is more limited in children. Viral loads, neutralising antibody titers⁴⁶, and T cell responses⁴⁷ impact clinical severity of COVID-19.

Cross-reactive T cell responses in unexposed adults have been mapped to have been NSPs of ORF1ab and Spike¹⁶, whilst recent infection boosts structural Spike and N specific T cells^17,18. The specificity of SARS-CoV-2 antibody landscapes differs in infected children to adults^44,48, with an increased contribution by accessory proteins and lower total magnitude of responses⁴⁸, whilst the ORF1ab antibody response is under characterised. SARS-CoV-2 antibody landscapes indicate that the specificity and balance of the adaptive immune responses in children are different from adults.

Overall, we found total IFNγ CD4⁺ and CD8⁺ T cell responses are significantly lower in SARS-CoV-2 infected children than adults against the viral structural proteins, and in CD8⁺ T cells against ORF1ab proteins. Whilst infected adults had markedly higher structural specific CD4⁺ T cell responses than negative adults, it was only after normalisation that infected children’s responses showed a significant increase compared to uninfected children, however these responses were still lower than infected adults. However, the T cell responses from infected children (at memory timepoints) had lower maximal activation compared to uninfected children negative controls. This may indicate T cell activation is refractory based on recent infection⁴⁹, and that SARS-CoV-2 infected children have dampened T cell responses.

The differences between infected children and adults may be due to differences in prior immunity to seasonal human coronaviruses through infection⁵⁰, resulting in qualitative differences in antigen-experienced CD4⁺ T cell responses in children. Children experience greater fold changes in influenza-specific T cell responses compared to adults during live attenuated influenza vaccination⁵¹, whereas we found lower SARS-CoV-2 T cell response magnitudes in children, however their fold changes and polyfunctional cytokines of the T cell responses was comparable between adults and children. Therefore there is equal recruitment of SARS-CoV-2 T cell responses in adults and children but likely different baseline levels of cross-reactive responses to recruit from, which is also indicated by increased Tfh recruitment in children for driving antibody responses, higher effector memory T cells in adults, and higher β-coronavirus OC43 specific IgG in adults. The smaller magnitude of SASR-CoV-2 memory T cell responses in children than adults, may imply a weaker long-term memory response in children potentially impacting outcomes at reinfection. Indeed, we found significantly lower levels of β-coronavirus specific antibodies in infected children than adults, and there was a significant trend for both increased SARS-CoV-2 specific T cell responses and OC43-specific IgG with increasing age. Recently, similar results were found in healthy adults as HKU-1 IgG showed an increasing trend with SARS-CoV-2 specific T cell responses of memory phenotype in uninfected adults¹⁵. A borderline trend for decreasing acute activated Tfh with higher OC43-specific IgG levels also suggests a greater importance CD4⁺ T cell recruitment in more immunologically naïve settings, and as β-coronavirus specific IgG levels increase there is a decreasing drive for Tfh recruitment. Only the quantification of baseline T cell responses specific for common cold viruses and subsequent exposure to SARS-CoV-2 in further studies, such as in human cohort transmission settings or animal models, will determine if prior β-coronavirus immunity, based on T or B cells, has a protective role in COVID-19.

The quality of T cell responses, assessed by SARS-CoV-2 specific T cell polyfunctional cytokine production and exhaustion marker (PD-1) expression, was equivalent between children and adults, reflecting comparable division and terminal differentiation. The matched quality of response but the higher threshold for IFNγ production by T cells in children may drive a less inflammatory environment that promotes more mild COVID-19 outcomes in children. There was different recruitment of innate and adaptive cellular responses in adults and children during SARS-CoV-2 infection likely driven by a difference in inflammatory milieu despite comparable symptom severity (mild/asymptomatic in our study). Children had increased Tfh recruitment, comparable plasmablast responses, but reduced inflammatory monocytes, specific CD4⁺ and CD8⁺ T cell responses, in both magnitude and proportion of responders. Further mechanistic studies are needed to define the basis of immunological differences between T cell responses of children and adults indicated in our study.

We found that children had increased activated Tfh responses compared with both adults and negative children, but lower IFNγ⁺ CD4⁺ T cells than adults. Therefore the CD4⁺ T cell compartment is modulated by SARS-CoV-2 infection, and more so than the CD8⁺ T cell response which is lagging behind and is only boosted at convalescence. In the early stages of infection, infected adults had significantly higher CD4⁺ T cell responses to viral structural/ORF1ab proteins but CD8⁺ T cell responses were unremarkable. CD8⁺ T cell responses increased later in the course of the infection, suggesting that they may not be playing a major role in the recovery from the acute illness. This may also explain why patients continue to shed virus RNA detectable by RT-PCR for a prolonged period of time during convalescence⁵². The persistence of virus replication may also drive the SARS-CoV-2 CD4⁺ T cell response to also remain stable with time.

The contribution of different virion structural and nonstructural proteins reflects MHC processing access during viral replication, whereby MHCII access to structural proteins elicited substantial CD4⁺ T cell responses in adults, whereas in children the CD4⁺ T cell response was predominantly ORF1ab specific. The imbalance of peptide specificities for nonstructural proteins for children’s CD4⁺ T cell compartment may indicate either different virus replication and pathogenesis at the cellular level or incomplete recruitment of de novo CD4⁺ T cell responses. Previously, in MERS-CoV infection, the magnitude of the CD4⁺ T cell response is proportional to virus replication and duration of illness²⁹. This is consistent with the mild outcomes of COVID-19 in children and reduced T cell responses reported here in our study of mild and asymptomatic SARS-CoV-2 infection. We cannot attribute the differences in T cell response magnitude with the severity of illness in children to adults, unlike other reports⁴⁷, as the majority of both infections we studied are mild or asymptomatic. Therefore children have reduced SARS-CoV-2 T cell responses due to lower baseline immune activation, and further research is still needed to discern the protective role of T cells in COVID-19.

Methods

Study population and clinical samples

Our study used samples from 24 children and 45 adults with RT-PCR confirmed SARS-CoV-2 infection in Hong Kong (Table 1). The days after onset of symptoms (for symptomatic infections) and days after first RT-PCR confirmation (for asymptomatic infections) were noted. All symptomatic or asymptomatic RT-PCR confirmed infections were hospitalised. Heparinised blood was collected at hospital admission (range: 1–14 days post symptom onset and/or RT-PCR confirmed infection), at discharge (range: 6–60 days), and at regular intervals after discharge for convalescent and long-term memory (range: 61–180 days) (Fig. 1a). We used samples from a total of 45 adults (mean±stdev: 43.1 ± 13.7, range: 20–65 years) and 24 children (8.1 ± 3.9, 1.92 (23 months)−13 years). We had 95 longitudinal samples from 46 subjects with 2 to 3 sampling time-points and 55 early acute time-points samples (< day 14) (Fig. 1a). Samples of comparable time-points were used from children (32.5 ± 40.4, 2–138 days) and adults (28.9 ± 39.6, 1–180 days) (Table 1). In experiments that include uninfected children controls, we used blood samples from a further 15 SARS-CoV-2 infected children (7.4 ± 4.4 years, 7 months–14 years) and 15 adults (41.7 ± 12.5, 24–61 years).

Table 1 Summary of cohort information.

Full size table

The study was approved by the institutional review board of the respective hospitals, viz. Kowloon West Cluster (KW/EX-20-039 (144-27)), Kowloon Central/Kowloon East cluster (KC/KE-20-0154/ER2) and HKU/HA Hong Kong West Cluster (UW 20-273, UW20-169), Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (CREC 2020.229). All patients, children, and their parents provided informed consent. The collection of SARS-CoV-2 seronegative adult negative control blood donors (37.6 ± 13.0, 19–57 years) was approved by the Institutional Review Board of The Hong Kong University and the Hong Kong Island West Cluster of Hospitals (UW16-254). SARS-CoV-2 seronegative children’s control blood donors (n = 15) were recruited from immunocompetent children from renal, endocrine, and blood clinics (10.3 ± 3.2, 2–14 years) who were donating blood for non-infection related purposes. Informed consent was given by patients and parents and the collection of these samples was approved by HKU/HA Hong Kong West Cluster Hospitals (UW 20-273, UW20-169).

Plasma was isolated, stored at −80 ^oC, and heat-inactivated (HI) at 56 °C for 30 min upon testing. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Paque (GE Healthcare) separation using Leucosep tubes (Greiner Bio-one) and cryopreserved in liquid nitrogen for batched analysis.

SARS-CoV-2 overlapping peptide pools for T cell stimulation

An overlapping peptide library was made covering the whole SARS-CoV-2 proteome with 20 amino acid (aa) length and 10 aa overlap (Genscript). The amino acid sequence of the peptide pools was based on βCoV/Hong Kong/VM20001061/2020 strain (GISAID ID: EPI_ISL_412028). Peptides were dissolved in deionised water, 10% acetic acid, or DMSO according to their biochemical properties and charge. A pool of 197 peptides representing Structural proteins: from S (1273aa, 127 peptides), N (419aa, 41 peptides), E (75aa, 7 peptides), M (222aa, 22 peptides), with a DMSO concentration of 0.6%. The ORF1ab peptide pool consisted of 709 peptides for the NSP1-16 proteins (7096aa), with a DMSO concentration of 2.1%. An accessory peptide pool of 69 peptides for the ORF3a (275aa, 27 peptides), ORF3b (43aa, 5 peptides), ORF6 (61aa, 6 peptides), ORF7a (121aa, 12 peptides), ORF7b (43aa, 3 peptides), ORF8 (121aa, 12 peptides), ORF10 (43aa, 3 peptides) proteins with a DMSO concentration of 0.2% (Fig. 1b). Experimental controls included: cytomegalovirus (CMV) peptide pool¹⁶ and PMA/ionomycin as positive controls and for negative controls media alone and average DMSO control (1.0% concentration) for background cytokine production (Supplementary Figure 1b). SARS-CoV-2 peptide Megapools (Spike plus all pool, 467 peptides) for predicted MHC restricted peptides covering all proteins of the genome for CD4⁺ T cells and CMV from Grifoni et al. were used as initial positive controls¹⁶.

SARS-CoV-2-specific T cell intracellular cytokine staining

Cryopreserved PBMCs were thawed and re-stimulated with overlapping peptide pools representing the SARS-CoV-2 structural proteins, accessory proteins, or ORF1ab (300 nM), DMSO (1% in RPMI), CMV peptide pool, PMA/ionomycin (1% in PBS) or RPMI alone for 6 h at 37 ^oC. Golgi Plug (BD) containing Brefeldin A (1% in PBS), and Golgi Stop (BD) containing Monensin (0.67% in PBS) were added at 2 h during stimulation. Cells were stained (all antibodies from Biolegend, catalogue number, clone and dilution used) with Zombie-NIR (423106, 1:1,000) followed by anti-human CD3-PE/Dazzle 594 (980006, UCHT1, 1:200), CD4-BV605 (317438, OKT4, 1:100), CD8-AlexaFluor700 (344724, SK1, 1:100), CCR7-PerCP/Cy5.5 (353220, G043H7, 1:20), PD-1-BV421 (367422, NAT105, 1:50), CD25-PE (302606, BC96, 1:100) and CD45RA-APC (983004, HI100, 1:200) and a dump channel containing CD19-BV510 (302242, HIB19, 1:100), CD56-BV510 (318340, HCD56, 1:100) and CD14-BV510 (301842, M5E2, 1:100). Cells were then permeabilised and fixed (BD Cytofix/cytoperm) and further stained for anti-human IFNγ-FITC (502506, 4 S.B3, 1:50), IL-2-PECy7 (500326, MQ1-17H12, 1:50), TNF-BV711 (502940, MAb11, 1:50). For experiments including IL4 staining, an alternative antibody cocktail was used, following cell permeabilisation, intracellular staining with anti-IFNγ-FITC, IL4-PE (500810, MP4-25D2, 1:50) and TNF-BV711 was carried out before acquisition of samples.

Activation-induced markers were detected following stimulation with the Structural peptide pool at a concentration of 2 µM or DMSO (1% in RPMI) with CD154-PE/Dazzle 594 (310840, 24-31, 1:100) for 18 h. Zombie-NIR staining was followed by anti-human CD4-BV605, CD8-AlexaFluor700, CCR7-PerCP/Cy5.5, PD-1-BV421, and CD45RA-APC, with the same dump channel were used again, with the addition of anti-human OX40-PE (350004, ACT35, 1:100), CD137-BV711 (309832, 4B4-1, 1:50), CD69-FITC (310904, FN50, 1:100) and CXCR5-PE-Cy7 (145516, L138D7, 1:50). Stained cells were acquired via flow cytometry (AttuneNxT) and analysed by FlowJo v10 (Supplementary Figure 1). IFNγ and AIM experiments were repeated twice on independent samples.

Immunostaining of monocytes, T follicular helper cells, and plasmablasts

Whole blood samples were stained with an antibody panel (all Biolegend and clone used) and live/dead Zombie-NIR to identify monocytes, Tfh, and plasmablast responses (Supplementary Figure 3). The combined monocytes/plasmablast panel contained: anti-human CD16-PE (980102, 3G8, 1:200), CD14-PerCPCy5.5 (301824, M5E2, 1:100), HLA-DR-BV605 (307640, L243, 1:75), CCR2-APC (357208, K035C2, 1:100), CD19-BV510 (302242, HIB19, 1:100), CD27-FITC (356404, M-T271, 1:50) and CD38-BV421 (303526, HIT2, 1:100). The Tfh panel contained: anti-human CD4-AlexaFluor700 (344622, SK3, 1:100), CXCR5-PerCPCy5.5 (356910, J252D4, 1:50), CD45RA-FITC (983002, HI100, 1:200), PD-1-BV711 (329928, EH12.2H7, 1:50) and ICOS-PE (313508, C398.4 A, 1:50). Cells were acquired by flow cytometry (AttuneNxT) and analysed by FlowJo v10 (Supplementary Figure 3).

Spike-IgG quantification by ELISA

Plates (Nunc MaxiSorp, Thermofisher Scientific) were coated with one representative coronavirus Spike protein at a time. Plates were coated with either 80 ng/ml of purified baculovirus-expressed Spike protein from 229E, NL63, HKU-1, and OC43 (SinoBiological). Plates were rinsed, blocked with 1% FBS in PBS, incubated with 1:100 HI plasma diluted in 0.05% Tween-20/ 0.1% FBS in PBS for 2 h then rinsed again, and incubated for 2 h with IgG-HRP (555788, G8-185, 1:5000; BD). HRP was revealed by stabilised hydrogen peroxide and tetramethylbenzidine (R&D systems) for 20 min, stopped with 2 N sulphuric acid and absorbance values were recorded at 450 nm on a spectrophotometer (Tecan Life Sciences).

Statistics and reproducibility

Statistical analysis was performed on Prism 9 (Graphpad). For two-way comparison, the Wilcoxon signed-rank test (paired) or Mann–Whitney t-test (unpaired) was used. For multiple-group comparisons, a Friedman (paired) or Kruskal–Wallis (unpaired) test, followed by the Dunn-Bonferroni post-hoc test was used. The One-sample Wilcoxon signed-rank test was used for comparisons against a hypothetical value of 1 for fold changes. Correlations were performed using the Spearman’s test. To account for correlation due to multiple measurements from the same patients, a linear random-effects model was fitted (Supplementary Table 1). The model also tested the linear time trend by days after illness onset, and potential differences by age, sex, and symptomatic patients. Differences were tested using Mann–Whitney test. Differences in baseline characteristics were detected with the chi-square test. Adjusted p values < 0.05 were considered statistically significant. Experiments were repeated successfully at least twice on independent samples.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The protein and peptide sequences and other data that support the findings of this study are available from the corresponding author upon reasonable request. The amino acid sequence of the peptide pools was based on βCoV/Hong Kong/VM20001061/2020 strain deposited in GenBank under accession code MT547814.1. Source data are provided in a Source Data file. Source data are provided with this paper.

References

Ing, A. J., Cocks, C. & Green, J. P. COVID-19: in the footsteps of Ernest Shackleton. Thorax 75, 693–694 (2020).
PubMed Google Scholar
Addetia, A. et al. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol. 58, e02107–20 (2020).
Article CAS PubMed PubMed Central Google Scholar
Lumley, S. F. et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med. 384, 533–540 (2021).
Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369, 812–817 (2020).
Article ADS CAS PubMed PubMed Central Google Scholar
Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 29, 44–57.e9 (2021).
Article CAS PubMed PubMed Central Google Scholar
Cele, S. et al. Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. Nature. 593, 142–146 (2021).
Article ADS CAS PubMed Google Scholar
Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 384, 238–251 (2021).
Article CAS PubMed Google Scholar
Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 592, 277–282 (2021).
Article CAS PubMed PubMed Central Google Scholar
Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045 (2020).
Article CAS PubMed PubMed Central Google Scholar
Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest 130, 2620–2629 (2020).
Article CAS PubMed PubMed Central Google Scholar
Wang, E. Y. et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 595, 283–288 (2021).
Article CAS PubMed Google Scholar
Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996–1012 (2020).
Article CAS PubMed PubMed Central Google Scholar
Anderson, E. M. et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell. 184, 1858–1864.e10 (2021).
Article CAS PubMed PubMed Central Google Scholar
Edridge, A. W. D. et al. Seasonal coronavirus protective immunity is short-lasting. Nat. Med 26, 1691–1693 (2020).
Article PubMed CAS Google Scholar
Tan, H. -X. et al. Adaptive immunity to human coronaviruses is widespread but low in magnitude. Clin Transl Immunology. 10 e1264 (2021).
Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501 (2020).
Article CAS PubMed PubMed Central Google Scholar
Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 370, 89–94 (2020).
Article ADS CAS PubMed PubMed Central Google Scholar
Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457–462 (2020).
Article PubMed CAS Google Scholar
Bacher, P. et al. Low-Avidity CD4(+) T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19. Immunity 53, 1258–1271 (2020).
Article CAS PubMed PubMed Central Google Scholar
McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 590, 630–634 (2021).
Article ADS CAS PubMed Google Scholar
Rodda, L. B. et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell 184, 169–183 (2021). e117.
Article CAS PubMed Google Scholar
Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med 26, 1200–1204 (2020).
Article CAS PubMed Google Scholar
Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158–168 (2020). e114.
Article CAS PubMed PubMed Central Google Scholar
Thevarajan, I. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat. Med 26, 453–455 (2020).
Article CAS PubMed Google Scholar
Chan, P. K. S. et al. Serologic responses in healthy adult with SARS-CoV-2 reinfection, Hong Kong, August 2020. Emerg. Infect. Dis. 26, 3076–3078 (2020).
Article CAS PubMed PubMed Central Google Scholar
Tosif, S. et al. Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19. Nat. Commun. 11, 5703 (2020).
Article ADS CAS PubMed PubMed Central Google Scholar
Juno, J. A. et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 26, 1428–1434 (2020).
Article CAS PubMed Google Scholar
Mok, C. K. P. et al. T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study. Lancet Infect Dis. 21, 385–395 (2021).
Article CAS PubMed Google Scholar
Zhao, J. et al. Recovery from the middle east respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol. 2, eaan5393 (2017).
Article PubMed PubMed Central Google Scholar
Lewis, D. B. et al. Cellular and molecular mechanisms for reduced interleukin 4 and interferon-gamma production by neonatal T cells. J. Clin. Invest 87, 194–202 (1991).
Article CAS PubMed PubMed Central Google Scholar
Rudolph, M. E. et al. Differences between pediatric and adult T cell responses to in vitro staphylococcal enterotoxin B stimulation. Front. Immunol. 9, 498 (2018).
Article PubMed PubMed Central CAS Google Scholar
Booth, J. S. et al. Characterization and functional properties of gastric tissue-resident memory T cells from children, adults, and the elderly. Front. Immunol. 5, 294 (2014).
Article PubMed PubMed Central CAS Google Scholar
Zhang, D. et al. Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. J. Leukoc. Biol. 109, 13–22 (2021).
Article CAS PubMed Google Scholar
Mann, E. R. et al. Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. Sci Immunol. 5, eabd6197 (2020).
Article PubMed PubMed Central CAS Google Scholar
Pilkinton, M. A. et al. Greater activation of peripheral T follicular helper cells following high dose influenza vaccine in older adults forecasts seroconversion. Vaccine 35, 329–336 (2017).
Article CAS PubMed Google Scholar
Lichterfeld, M. et al. HIV-1–specific cytotoxicity is preferentially mediated by a subset of CD8+ T cells producing both interferon-γ and tumor necrosis factor–α. Blood 104, 487–494 (2004).
Article CAS PubMed Google Scholar
Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305–1312 (2013).
Article CAS PubMed Google Scholar
Denton, A. E., Russ, B. E., Doherty, P. C., Rao, S. & Turner, S. J. Differentiation-dependent functional and epigenetic landscapes for cytokine genes in virus-specific CD8+ T cells. Proc. Natl Acad. Sci. USA 108, 15306–15311 (2011).
Article ADS CAS PubMed PubMed Central Google Scholar
Kretschmer, L. et al. Differential expansion of T central memory precursor and effector subsets is regulated by division speed. Nat. Commun. 11, 113 (2020).
Article ADS CAS PubMed PubMed Central Google Scholar
Kinjyo, I. et al. Real-time tracking of cell cycle progression during CD8+ effector and memory T-cell differentiation. Nat. Commun. 6, 6301 (2015).
Article ADS CAS PubMed Google Scholar
Weninger, W., Crowley, M. A., Manjunath, N. & von Andrian, U. H. Migratory properties of naive, effector, and memory CD8(+) T cells. J. Exp. Med. 194, 953–966 (2001).
Article CAS PubMed PubMed Central Google Scholar
Selva, K. J. et al. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat Commun. 12, 2037 (2021).
Article ADS CAS PubMed PubMed Central Google Scholar
Jones, T. C. et al. An analysis of SARS-CoV-2 viral load by patient age. Science. 373, eabi5273 (2021).
Article CAS PubMed Google Scholar
Weisberg, S. P. et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat. Immunol. 22, 25–31 (2021).
Article PubMed Google Scholar
Lau, E. H. Y. et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat. Commun. 12, 63 (2021).
Article ADS CAS PubMed PubMed Central Google Scholar
Garcia-Beltran, W. F. et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 184, 476–488.e11 (2021).
Article CAS PubMed Google Scholar
Peng, Y. et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336–1345 (2020).
Article CAS PubMed PubMed Central Google Scholar
Hachim, A. et al. The SARS-CoV-2 antibody landscape is lower in magnitude for structural proteins, diversified for accessory proteins and stable long-term in children. medRxiv https://doi.org/10.1101/2021.01.03.21249180 (2021).
Crawford, T. Q., Hecht, F. M., Pilcher, C. D., Ndhlovu, L. C. & Barbour, J. D. Activation associated ERK1/2 signaling impairments in CD8+ T cells co-localize with blunted polyclonal and HIV-1 specific effector functions in early untreated HIV-1 infection. PLoS One 8, e77412 (2013).
Article ADS CAS PubMed PubMed Central Google Scholar
Shannon, I. et al. Differences in the influenza-specific CD4 T cell immunodominance hierarchy and functional potential between children and young adults. Sci. Rep. 9, 791 (2019).
Article ADS PubMed PubMed Central CAS Google Scholar
He, X. S. et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol. 80, 11756–11766 (2006).
Article CAS PubMed PubMed Central Google Scholar
Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 591, 639–644 (2021).
Article ADS CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

This study was partly supported by the Theme based Research Grants Scheme (T11-712/19-N), Health and Medical Research Fund (HMRF COVID-190115 and COVID-190126), National Institutes of Allergy and Infectious Diseases, National Institutes of Health (USA) (HHSN272201400006C and U01AI151810). We thank Daniela Weiskopf, Jose Barrera, Shane Crotty, and Alessandro Sette from La Jolla Institute, USA, for providing SARS-CoV-2 peptide Megapools. This project utilised an Invitrogen Attune flow cytometer assisted by the Pasteur Foundation Asia.

Author information

Authors and Affiliations

HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China
Carolyn A. Cohen, Athena P. Y. Li, Asmaa Hachim, Niloufar Kavian, Fionn N. L. Ma, Leo L. M. Poon, Malik Peiris & Sophie A. Valkenburg
Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, SAR, China
David S. C. Hui
Department of Paediatric and Adolescent Medicine, Hong Kong Hospital Authority Infectious Disease Center, Princess Margaret Hospital, Hong Kong, SAR, China
Mike Y. W. Kwan
Infectious Diseases Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong, Hong Kong SAR, China
Owen T. Y. Tsang
Department of Paediatric and Adolescent Medicine, The University of Hong Kong and Queen Mary Hospital, Hospital Authority of Hong Kong, Hong Kong SAR, China
Susan S. Chiu
Department of Paediatrics, Queen Elizabeth Hospital, Hospital Authority of Hong Kong, Hong Kong SAR, China
Wai Hung Chan & Yat Sun Yau
WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China
Eric H. Y. Lau
Division of Public Health Laboratory Sciences, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China
Samuel M. S. Cheng, Leo L. M. Poon & Malik Peiris

Authors

Carolyn A. Cohen
View author publications
You can also search for this author in PubMed Google Scholar
Athena P. Y. Li
View author publications
You can also search for this author in PubMed Google Scholar
Asmaa Hachim
View author publications
You can also search for this author in PubMed Google Scholar
David S. C. Hui
View author publications
You can also search for this author in PubMed Google Scholar
Mike Y. W. Kwan
View author publications
You can also search for this author in PubMed Google Scholar
Owen T. Y. Tsang
View author publications
You can also search for this author in PubMed Google Scholar
Susan S. Chiu
View author publications
You can also search for this author in PubMed Google Scholar
Wai Hung Chan
View author publications
You can also search for this author in PubMed Google Scholar
Yat Sun Yau
View author publications
You can also search for this author in PubMed Google Scholar
Niloufar Kavian
View author publications
You can also search for this author in PubMed Google Scholar
Fionn N. L. Ma
View author publications
You can also search for this author in PubMed Google Scholar
Eric H. Y. Lau
View author publications
You can also search for this author in PubMed Google Scholar
Samuel M. S. Cheng
View author publications
You can also search for this author in PubMed Google Scholar
Leo L. M. Poon
View author publications
You can also search for this author in PubMed Google Scholar
Malik Peiris
View author publications
You can also search for this author in PubMed Google Scholar
Sophie A. Valkenburg
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

C. A. C. performed experiments. C. A. C., A. P. Y. L., A. H., N. K. and S. A. V. designed experiments. M. Y. W. K., W. H. C., Y. S. Y., S. S. C. O. T. Y. T., D. S. C. H. provided clinical information and supplied clinical samples, processed by F. N. L. M. coordinated by S. M. S. C. E. H. Y. L. performed further analysis. C. A. C., L. P., J. S. M. P. and S. A. V. designed the study. C. A. C., A. P. Y. L., A. H., N. K., L. P., J. S. M. P. and S. A. V. interpreted results and wrote the paper.

Corresponding author

Correspondence to Sophie A. Valkenburg.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Peer Review File

Reporting Summary

Source data

Source Data

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Cohen, C.A., Li, A.P.Y., Hachim, A. et al. SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection. Nat Commun 12, 4678 (2021). https://doi.org/10.1038/s41467-021-24938-4

Download citation

Received: 22 February 2021
Accepted: 14 July 2021
Published: 29 July 2021
DOI: https://doi.org/10.1038/s41467-021-24938-4

This article is cited by

Latent and incubation periods of Delta, BA.1, and BA.2 variant cases and associated factors: a cross-sectional study in China
- Yu Li
- Xinli Jiang
- Zhongjie Li
BMC Infectious Diseases (2024)
Natural and hybrid immunity after SARS-CoV-2 infection in children and adolescents
- T. Rothoeft
- C. Maier
- F. Brinkmann
Infection (2024)
Severe pediatric COVID-19: a review from the clinical and immunopathophysiological perspectives
- Yi-Kan Sun
- Can Wang
- Lin-Hua Tan
World Journal of Pediatrics (2024)
Weighted gene co-expression network analysis revealed T cell differentiation associated with the age-related phenotypes in COVID-19 patients
- Yao Lin
- Yueqi Li
- Sanqi An
BMC Medical Genomics (2023)
Fading SARS-CoV-2 humoral VOC cross-reactivity and sustained cellular immunity in convalescent children and adolescents
- Krystallenia Paniskaki
- Sarah Goretzki
- Nina Babel
BMC Infectious Diseases (2023)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.